Anemia in chronic kidney disease (CKD) is common, causing morbidity and mortality, and is primarily due to reduced erythropoietin (EPO) release and, to a lesser degree, shortened red cell survival. Erythropoietin Stimulating Agents like epoetin Alfa and darbepoetin alpha are used commonly to treat this form of anemia. Recent evidence suggests increased morbidity and mortality associated with higher hemoglobin in the setting of these agents use. Whether these complications are due to higher dose of erythropoietin or its resistance ( i.e. inflammation), or achieving a higher hemoglobin remains unclear. Tightening restrictions on these agents has led to increase interest in the use of non-ESA adjuvants to improve erythropoiesis. This review will highlight the most promising of these agents.
[1] F. Valderrababano, “Erythropoietin in Chronic Renal Failure,” Kidney International, Vol. 50, No. 4, 1996, pp. 1373-1391. doi:10.1038/ki.1996.452
J. W. Eschbach, “Erythropoietin 1991—An Overview,” American Journal of Kidney Diseases, Vol. 18, Suppl. 4, 1991, pp. 3-9.
B. C. Astor, P. Muntner, A. Levin, J. A. Eustace and J. Coresh, “Association of Kidney Function With Anemia: The Third National Health and Nutrition Examination Survey (1988-1994),” Archives of Internal Medicine, 2002, Vol. 162, No. 12, pp. 1401-1408. doi:10.1001/archinte.162.12.1401
A. Levin, C. R. Thompson, J. Ethier, E. J. Carlisle, S. Tobe, D. Mendelssohn, E. Burgess, K. Jindal, B. Barrett, J. Singer and O. Djurdjev, “Left ventricular Mass Index Increase in Early Renal Disease: Impact of Decline in Hemoglobin,” American Journal of Kidney Diseases, Vol. 34, No. 1, 1999, pp. 125-134. doi:10.1016/S0272-6386(99)70118-6
C. T. Jurkovitz, J. L. Abramson, L. V. Vaccarino, W. S. Weintraub and W. M. McClellan, “Association of High Serum Creatinine and Anemia Increases the Risk of Coronary Events: Results from the Prospective Community-Based Atherosclerosis Risk in Communities (ARIC) Study,” Journal of the American Society of Nephrology, Vol. 14, No. 11, 2003, pp. 2919-2925. doi:10.1097/01.ASN.0000092138.65211.71
J. L. Abramson, C. T. Jurkovitz, V. Vaccarino, W. S. Weintraub and W. McClellan, “Chronic Kidney Disease, Anemia, and Incident Stroke in a Middle-Aged, Community-Based Population: The ARIC Study,” Kidney International, Vol. 64, No. 2, 2003, pp. 610-615. doi:10.1046/j.1523-1755.2003.00109.x
M. J. Sarnak, H. Tighiouart, G. Manjunath, B. MacLeod, J. Griffith, D. Salem and A. S. Levey, “Anemia as a Risk Factor for Cardiovascular Disease in the Atherosclerosis Risk in Communities (ARIC) Study,” Journal of the American College of Cardiology, Vol. 40, No. 1, 2002, pp. 27-33. doi:10.1016/S0735-1097(02)01938-1
W. M. McClellan, W. D. Flanders, R. D. Langston, C. Jurkovitz and R. Presley, “Anemia and Renal Insufficiency Are Independent Risk Factors for Death among Patients with Congestive Heart Failure Admitted to Community Hospitals: A Population-Based Study,” Journal of the American Society of Nephrology, Vol. 13, No. 7, 2002, pp. 1928-1936. doi:10.1097/01.ASN.0000018409.45834.FA
G. T. Obrador, T. Roberts, W. L. St Peter, E. Frazier, B. J. Pereira and A. Collins, “Trends in Anemia at Initiation of Dialysis in the United States,” Kidney International, Vol. 60, No. 5, 2001, pp. 1875-1884. doi:10.1046/j.1523-1755.2001.00002.x
M. A. Pfeffer, E. A. Burdmann, C. Y. Chen, M. E. Cooper, D. de Zeeuw, K. U. Eckardt, J. M. Feyzi, P. Ivanovich, R. Kewalramani, A. S. Levey, E. F. Lewis, J. B. McGill, J. J. McMurray, P. Parfrey, H. H. Parving, G. Remuzzi, A. K. Singh, S. D. Solomon and R. Toto, “TREAT Investigators a Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease,” New England Journal of Medicine, Vol. 361, No. 21, 2009, pp. 2019-2032. doi:10.1056/NEJMoa0907845
T. B. Drüeke, F. Locatelli, N. Clyne, K. U. Eckardt, I. C. Macdougall, D. Tsakiris, H. U. Burger and A. Scherhag, “CREATE Investigators Normalization of Hemoglobin Level in Patients with chronic Kidney Disease and Anemia,” New England Journal of Medicine, Vol. 355, No. 20, 2006, pp. 2071-2084. doi:10.1056/NEJMoa062276
A. K. Singh, L. Szczech, K. L. Tang, H. Barnhart, S. Sapp, M. Wolfson and D. Reddan, “CHOIR Investigators Correction of Anemia with Epoetin Alfa in Chronic Kid- ney Disease,” New England Journal of Medicine, Vol. 355, No. 20, 2006, pp. 2085-2098. doi:10.1056/NEJMoa065485
http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm
“KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease,” Kidney International Supplements, Vol. 2, Vol. 4, 2012, pp. 279-335.
J. W. Eschbach, J. D. Cook, B. H. Scribner, C. A. Finch, “Iron Balance in Hemodialysis Patients,” Annals of Internal Medicine, Vol. 87, No. 6, 1977, pp. 710-713.
A. M. Fernández-Rodríguez, M. C. Guindeo-Casasús, T. Molero-Labarta, C. Domínguez-Cabrera, L. Hortal-Casc, P. Pérez-Borges, N. Vega-Díaz, P. Saavedra-Santana and L. Palop-Cubillo, “Diagnosis of Iron Deficiency in Chronic Renal Failure,” American Journal of Kidney Diseases, Vol. 34, No. 3, 1999, pp. 508-513.
M. Rambod, C. P. Kovesdy, K. Kalantar-Zadeh, “Combined High Serum Ferritin and Low Iron Saturation in Hemodialysis Patients: The Role of Inflammation,” Clinical Journal of the American Society of Nephrology, Vol. 3, No. 6, 2008, pp. 1691-1701. doi:10.2215/CJN.01070308
F. N. Hutchinson and W. J. Jones, “A Cost-Effectiveness Analysis of Anemia Screening before Erythropoietin in Patients with End Stage Renal Disease,” American Journal of Kidney Diseases, Vol. 29, No. 5, 1997, pp. 651-657. doi:10.1016/S0272-6386(97)90116-5
D. W. Coyne, T. Kapoian, W. Suki, et al., “Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study,” Journal of the American Society of Nephrology, Vol. 18, No. 3, 2007, pp. 975-984. doi:10.1681/ASN.2006091034
A. K. Singh, D. W. Coyne, W. Shapiro, A. R. Rizkalaand DRIVE Study Group, “Predictors of the Response to Treatment in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation,” Kidney International, Vol. 71, No. 11, 2007, pp. 1163-1171.
G. Nicolas, M. Bennoun, I. Devaux, et al., “Lack of Hepcidin Gene Expression and Severe Tissue Iron Overload in Upstream Stimulatory Factor 2 (USF2) Knockout Mice,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, No. 15, 2001, pp. 8780-8785. doi:10.1073/pnas.151179498
E. Nemeth and T. Ganz, “Regulation of Iron Metabolism by Hepcidin,” Annual Review of Nutrition, Vol. 26, No. 1, 2006, pp. 323-342. doi:10.1146/annurev.nutr.26.061505.111303
D. Coyne, “Iron Indices: What Do They Really Mean?” Kidney International, Vol. 69, 2006, pp. S4-S8. doi:10.1038/sj.ki.5000404
N. Tomosugi, H. Kawabata, R. Wakatabe, et al., “Detection of Serum Hepcidin in Renal Failure and Inflammation by Using ProteinChip System,” Blood, Vol. 108, No. 4, 2006, pp. 1381-1387. doi:10.1182/blood-2005-10-4043
D. R. Ashby, D. P. Gale, M. Busbridge, et al., “Plasma Hepcidin Levels Are Elevated but Responsive to Erythropoietin Therapy in Renal Disease,” Kidney International, Vol. 75, No. 9, 2009, pp. 976-981. doi:10.1038/ki.2009.21
J. Zaritsky, B. Young, H. J. Wang, et al., “Hepcidin—A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease,” Clinical Journal of the American Society of Nephrology, Vol. 4, No. 6, 2009, pp. 1051-1056 doi:10.2215/CJN.05931108
H. P. Peters, C. M. Laarakkers, D. W. Swinkels, et al., “Serum Hepcidin-25 Levels in Patients with Chronic Kidney Disease Are Independent of Glomerular Filtration Rate,” Nephrology Dialysis Transplantation, Vol. 25, No. 3, 2010, pp. 848-853. doi:10.1093/ndt/gfp546
G. Weiss, I. Theurl, S. Eder, et al., “Serum Hepcidin Concentration in Chronic Haemodialysis Patients: Associations and Effects of Dialysis, Iron and Erythropoietin Therapy,” European Journal of Clinical Investigation, Vol. 39, No. 10, 2009, pp. 883-890. doi:10.1111/j.1365-2362.2009.02182.x
B. Ford, C. Eby, M. Scott, et al., “Intra-Individual Variability in Serum Hepcidin Precludes Its Use as a Marker of Iron Status in Hemodialysis Patients,” Kidney International, Vol. 78, 2010, pp. 769-773. doi:10.1038/ki.2010.254
S. Stancu, L. Barsan, A. Stanciu, et al., “Can the Response to Iron Therapy Be Predicted in Anemic Nondialysis Patients with Chronic Kidney Disease?” Clinical Journal of the American Society of Nephrology, Vol. 5, No. 3, 2010, pp. 409-416. doi:10.2215/CJN.04280609
B. J. Sasu, K. S. Cooke, T. L. Arvedson, et al., “Antihepcidin Antibody Treatment Modulates Iron Metabolism and Is Effective in a Mouse Model of Inflammation-Induced Anemia,” Blood, Vol. 115, No. 17, 2010, pp. 3616-3624. doi:10.1182/blood-2009-09-245977
R. Fudin, J. Jaichenko, A. Shostak, M. Bennett and L. Gotloib, “Nephron Correction of Uremic Iron Deficiency Anemia in Hemodialyzed Patients: A Prospective Study,” Vol. 79, No. 3, 1998, pp. 299-305. doi:10.1159/000045053
I. C. MacDougall, B. Tucker, J. Thompson, C. R. Tomson, L. R. Baker and A. E. Raine, “A Randomized Controlled Study of Iron Supplementation in Patients Treated with EPO,” Kidney International, Vol. 50, No. 5, 1996, pp. 1694-1699. doi:10.1038/ki.1996.487
R. L. Wingard, R. A. Parker, N. Ismail and R. M. Hakim, “Efficacy of Oral Iron Therapy in Patients Receiving Recombinant Human EPO,” American Journal of Kidney Diseases, Vol. 25, No. 3, 1995, pp. 433-439. doi:10.1016/0272-6386(95)90105-1
R. Provenzano, B. Schiller, M. Rao, D. Coyne, L. Brenner and B. J. Pereira, “Ferumoxytol as an Intravenous Iron Replacement Therapy iN Hemodialysis Patients,” Clinical Journal of the American Society of Nephrology, Vol. 4, No. 2, 2009, pp. 386-393. doi:10.2215/CJN.02840608
“K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,” American Journal of Kidney Diseases, Vol. 47, Suppl. 3, 2006, pp. S1-S3. doi:10.1053/S0272-6386(05)01814-7
J. Stoves, H. Inglis and C. G. Newstead, “A Randomized Study of Oral vs. Intravenous Iron Supplementation in Patients with Progressive Renal Insufficiency Treated with EPO,” Nephrology Dialysis Transplantation, Vol. 16, No. 5, 2001, pp. 967-974. doi:10.1093/ndt/16.5.967
C. Charytan, W. Ounibi and G. R. Bailie, “Comparison of Intravenous Iron Sucrose to Oral Iron in the Treatment of Anemic Patients with Chronic Kidney Disease Not on Dialysis,” Nephron Clinical Practice, Vol. 100, No. 3, 2005, pp. c55-c62.
D. B. Van Wyck; M. Roppolo, C. O. Martinez, R. M. Mazey and S. McMurray, “A Randomized, Controlled Trial Comparing IV Iron Sucrose to Oral Iron in Anemic Patients with Non Dialysis-Dependent CKD,” Kidney International, Vol. 68, No. 6, 2005, pp. 2846-2856 doi:10.1111/j.1523-1755.2005.00758.x
R. Agarwal, A. R. Rizkala, B. Bastani, M. O. Kaskas, D. J. Leehey and A. Besarab, “A Randomized Controlled Trial of Oral versus Intravenous Iron in Chronic Kidney Disease,” American Journal of Nephrology, Vol. 26, No. 5, 2006, pp. 445-454. doi:10.1159/000096174
B. S. Spinowitz, A. T. Kausz, J. Baptista, S. D. Noble, R. Sothinathan, M. V. Bernardo, L. Brenner and B. J. Pereira, “Ferumoxytol for Treating Iron Deficiency Anemia in CKD,” Journal of the American Society of Nephrology, Vol. 19, No. 8, 2008, pp. 1599-1605 doi:10.1681/ASN.2007101156
K. R. Bridges and K. E. Hoffman, “The Effects of Ascorbic Acid on the Intracellular Metabolism of Iron and Ferritin,” Journal of Biological Chemistry, Vol. 261, No. 30, 1986, pp. 14273-14277.
D. A. Lipschitz, T. H. Bothwell, H. C. Seftel, et al., “The Role of Ascorbic Acid in the Metabolism of Storage Iron,” British Journal of Haematology, Vol. 20, No. 2, 1971, pp. 155-163. doi:10.1111/j.1365-2141.1971.tb07024.x
A. Goldberg, “The Enzymic Formation of Haem by the Incorporation of Iron into Protoporphyrin; Importance of Ascorbic Acid, Ergothioneine and Glutathione,” British Journal of Haematology, Vol. 5, No. 2, 1959, pp. 150-157. doi:10.1111/j.1365-2141.1959.tb04020.x
R. Deicher, F. Ziai, A. Habicht, et al., “Vitamin C Plasma Level and Response to Erythropoietin in Patients on Maintenance Haemodialysis,” Nephrology Dialysis Transplantation, 2004, Vol. 19, 2319. doi:10.1093/ndt/gfh260
K. Gastaldello, A. Vereerstraeten, T. Nzame-Nze, J. L. Vanherweghem and C. Tielemans, “Resistance to EPO in Iron-Overloaded Hemodialysis Patients Can Be Overcome by Ascorbic Acid Administration,” Nephrology Dialysis Transplantation, Vol. 10, Suppl. 6, 1995, pp. 44-47.
D. C. Tarng, Y. H. Wei, T. P. Huang, et al., “Intravenous Ascorbic Acid as an Adjuvant Therapy for Recombinant Erythropoietin in Hemodialysis Patients with Hyperferritinemia,” Kidney International, Vol. 55, No. 6, 1999, pp. 2477-2486. doi:10.1046/j.1523-1755.1999.00479.x
W. D. Sirover, A. A. Siddiqui and R. L. Benz, “Beneficial Hematologic Effects of Daily Oral Ascorbic Acid Therapy in ESRD Patients with Anemia and Abnormal Iron Homeostasis: A Preliminary Study,” Renal Failure, Vol. 30, No. 9, 2008, pp. 884-889. doi:10.1080/08860220802353884
K. Keven, S. Kutlay, G. Nergizoglu and S. Ertürk, “Randomized, Crossover Study of the Effect of Vitamin C on EPO Response in Hemodialysis Patients,” American Journal of Kidney Diseases, 2003, Vol. 41, No. 6, pp. 1233-1239. doi:10.1016/S0272-6386(03)00356-1
Y. Taji, T. Morimoto, K. Okada, et al., “Effects of Intravenous Ascorbic Acid on Erythropoiesis and Quality of Life in Unselected Hemodialysis Patients,” Journal of Nephrology, Vol. 17, No. 4, 2004, pp. 537-543.
J. Deira, J. Diego, R. Martínez, et al., “Comparative Study of Intravenous Ascorbic Acid versus Low-Dose Desferroxamine in Patients on Hemodialysis with Hyperferritinemia,” Journal of Nephrology, Vol. 16, No. 5, 2003, pp. 703-709.
V. Giancaspro, M. Nuzziello, G. Pallotta, et al., “Intravenous Ascorbic Acid in Hemodialysis Patients with Functional Iron Deficiency: A Clinical Trial,” Journal of Nephrology, Vol. 13, No. 6, 2000, pp. 444-449.
N. Attallah, Y. Osman-Malik, S. Frinak and A. Besarab, “Effect of Intravenous Ascorbic Acid in Hemodialysis Patients with EPO-Hyporesponsive Anemia and Hyperferritinemia,” American Journal of Kidney Diseases, Vol. 47, No. 4, 2006 pp. 644-654. doi:10.1053/j.ajkd.2005.12.025
V. Deved, P. Poyah, M. T. James, et al., “Ascorbic Acid for Anemia Management in Hemodialysis Patients: A Systematic Review and Meta-Analysis,” American Journal of Kidney Diseases, Vol. 54, No. 6, 2009, pp. 1089-1097. doi:10.1053/j.ajkd.2009.06.040
P. Balcke, P. Schmidt, J. Zazgornik, et al., “Ascorbic Acid Aggravates Secondary Hyperoxalemia in Patients on Chronic Hemodialysis,” Annals of Internal Medicine, Vol. 101, No. 3, 1984, pp. 343-344.
C. Pru, J. Eaton and C. Kjellstrand, “Vitamin C Intoxication and Hyperoxalemia in Chronic Hemodialysis Patients,” Nephron, Vol. 39, No. 2, 1985, pp. 112-116. doi:10.1159/000183353
J. Eiselt, J. Racek, L. Trefil and K. Opatrny Jr., “Effects of a Vitamin E-Modified Dialysis Membrane and Vitamin C Infusion on Oxidative Stress in Hemodialysis Patients,” Artificial Organs, 2001, Vol. 25, No. 6, pp. 430-436. doi:10.1046/j.1525-1594.2001.025006430.x
C. Canavese, M. Petrarulo, P. Massarenti, et al., “Long-Term, Low-Dose, Intravenous Vitamin C Leads to Plasma Calcium Oxalate Supersaturation in Hemodialysis Patients,” American Journal of Kidney Diseases, Vol. 45, No. 3, 2005, pp. 540-549. doi:10.1053/j.ajkd.2004.10.025
“SECTION III. Treatment of Renal Anaemia,” Nephrology Dialysis Transplantation, Vol. 19, Suppl. 2, 2004, pp. ii16-ii31. doi:10.1093/ndt/gfh1026
C. J. Rebouche and H. Seim, “Carnitine Metabolism and Its Regulation in Microorganisms and Mammals,” An- nual Review of Nutrition, Vol. 18, No. 1, 1998, pp. 39-61. doi:10.1146/annurev.nutr.18.1.39
T. A. Golper, S. Goral, B. N. Becker and C. B. Langman, “L-Carnitine Treatment of Anemia,” American Journal of Kidney Diseases, Vol. 41, Suppl. 42, 2003, pp. S27-S34. doi:10.1016/S0272-6386(03)00114-8
Y. Kitamura, K. Satoh, T. Satoh, et al., “Effect of L-Carnitine on Erythroid Colony Formation in Mouse Bone Marrow Cells,” Nephrology Dialysis Transplantation, Vol. 20, No. 5, 2005, pp. 981-984. doi:10.1093/ndt/gfh758
J. M. Hurot, M. Cucherat, M. Haugh and D. Fouque, “Effects of L-Carnitine Supplementation in Maintenance Hemodialysis Patients: A Systematic Review,” Journal of the American Society of Nephrology, Vol. 13, No. 2002, pp. 708-714.
W. D. Labonia, “L-Carnitine Effects on Anemia in Hemodialyzed Patients Treated with Erythropoietin,” American Journal of Kidney Diseases, 1995, Vol. 26, pp. 757-764. doi:10.1016/0272-6386(95)90439-5
A. A. Sabry, “The Role of Oral L-Carnitine Therapy in Chronic Hemodialysis Patients,” Saudi Journal of Kidney Diseases and Transplantation, Vol. 21, No. 3, 2010, pp. 454-459.
U. Caruso, L. Leone, E. Cravotto and D. Nava, “Effects of L-Carnitine on Anemia in Aged Hemodialysis Patients Treated with Recombinant Human Erythropoietin: A Pilot Study,” Dialysis & Transplantation, Vol. 27, 1998, pp. 498-506.
J. Kletzmayr, G. Mayer, E. Legenstein, et al., “Anemia and Carnitine Supplementation in Hemodialyzed Patients,” Kidney International Supplements, Vol. 55, Suppl. 69, 1999, pp. S93-S96. doi:10.1046/j.1523-1755.1999.055Suppl.69093.x
E. C. Vaux, D. J. Taylor, P. Altmann, et al., “Effects of Carnitine Supplementation on Muscle Metabolism by the Use of Magnetic Resonance Spectroscopy and near-Infrared Spectroscopy in End-Stage Renal Disease,” Nephron Clinical Practice, Vol. 97, No. 2, 2004, pp. c41-c48. doi:10.1159/000078399
J. Semeniuk, K. F. Shalansky, N. Taylor, et al., “Evaluation of the Effect of Intravenous L-Carnitine on Quality of Life in Chronic Hemodialysis Patients,” Clinical Nephrology, Vol. 54, No. 6, 2000, pp. 470-477.
A. Evans, “Dialysis-Related Carnitine Disorder and Levocarnitine Pharmacology,” American Journal of Kidney Diseases, Vol. 41, Suppl. 4, 2003, pp. S13-S26. doi:10.1016/S0272-6386(03)00113-6
M. A. Bain, R. Faull, R. W. Milne and A. M. Evans, “Oral L-Carnitine: Metabolite Formation and Hemodialysis,” Current Drug Metabolism, Vol. 7, No. 7, 2006, pp. 811-816. doi:10.2174/138920006778520561
G. Eknoyan, D. L. Latos and J. Lindberg, “National Kidney Foundation Carnitine Consensus Conference. Practice Recommendations for the Use of L-Carnitine in Dialysis-Related Carnitine Disorder. National Kidney Foundation Carnitine Consensus Conference,” American Journal of Kidney Diseases, Vol. 41, No. 4, 2003, pp. 868-876. doi:10.1016/S0272-6386(03)00110-0
J. Bienvenu, C. Doche, M. C. Gutowski, et al. “Production of Proinflammatory Cytokines and Cytokines Involved in the TH1/TH2 Balance is Modulated by Pen- toxifylline,” Journal of Cardiovascular Pharmacology, Vol. 25, Suppl. 2, 1995, pp. S80-S84. doi:10.1097/00005344-199500252-00017
N. Benbernou, S. Esnault, G. Potron and M. Guenounou, “Regulatory Effects of Pentoxifylline on T-Helper Cell-Derived Cytokine Production in Human Blood Cells,” Journal of Cardiovascular Pharmacology, Vol. 25, Suppl. 2, 1995, pp. S75-S79. doi:10.1097/00005344-199500252-00016
J. F. Navarro, C. Mora, J. García, et al., “Effects of Pentoxifylline on the Haematologic Status in Anaemic Patients with Advanced Renal Failure,” Scandinavian Journal of Urology and Nephrology, Vol. 33, 1999, pp. 121-125. doi:10.1080/003655999750016113
A. Cooper, A. Mikhail, M. W. Lethbridge, et al., “Pentoxifylline Improves Hemoglobin Levels in Patients with Erythropoietin-Resistant Anemia in Renal Failure,” Journal of the American Society of Nephrology, Vol. 15, No. 7, 2004, pp. 1877-1882. doi:10.1097/01.ASN.0000131523.17045.56
G. Sirken, S. C. Kung and R. Raja, “Decreased Erythropoietin Requirements in Maintenance Hemodialysis Patients with Statin Therapy,” Asaio Journal, Vol. 49, 2003, pp. 422-425.
K. Tangdhanakanond and R. Raja, “Effect of Statins on EPO Responsiveness in Type 2-Diabetic versus Non-Diabetic Hemodialysis Patients,” Clinical Nephrology, Vol. 73, No. 1, 2010, pp. 1-6.
C. K. Chiang, S. Y. Yang, Y. S. Peng, S. P. Hsu, M. F. Pai, J. W. Huang, K. Y. Hung and K. D. Wu, “Atorvastatin Increases EPO-Stimulating Agent Hypo Responsiveness in Maintenance Hemodialysis Patients: Role of Anti-Inflammation Effects,” American Journal of Nephrology, Vol. 29, No. 5, 2009, pp. 392-397. doi:10.1159/000169658
United States Renal Data System, “USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health,” National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2010.
J. L. Teruel, R. Marcen, J. Navarro-Antolin, A. Aguilera, G. Fernandez-Juarez and J. Ortuo, “Androgen versus EPO for the Treatment of Anemia in Hemodialyzed Patients: A Prospective Study,” Journal of the American Society of Nephrology, 1996, Vol. 7, No. 1, pp. 140-144.
A. Gascn, J. J. Belvis, F. Berisa, E. Iglesias, V. Estopin and J. L. Teruel, “Nandrolone Decanoate Is a Good Alternative for the Treatment of Anemia in Elderly Male Patients on Hemodialysis,” Geriatric Nephrology and Urology, Vol. 9, No. 2, 1999, pp. 67-72. doi:10.1023/A:1008306301255
J. F. Navarro, C. Mora-Fernandez, A. Rivero, M. Macia, E. Gallego, J. Chahin, M. L. Mendez and J. Garcia, “Androgens for the Treatment of Anemia in Peritoneal Dialysis Patients,” Advances in Peritoneal Dialysis, Vol. 14, 1998, pp. 232-235.
J. F. Navarro, C. Mora, M. Macia and J. Garcia, “Randomized Prospective Comparison between EPO and Androgens in CAPD Patients,” Kidney International, Vol. 61, No. 4, 2002, pp. 1537-1544. doi:10.1046/j.1523-1755.2002.00271.x
S. H. Ballal, D. T. Domoto, D. C. Polack, P. Marciulonis and K. J. Martin, “Androgens Potentiate the Effects of EPO in the Treatment of Anemia of End-Stage Renal Disease,” American Journal of Kidney Diseases, Vol. 17, No. 1, 1991, pp. 29-33.
J. S. Bern, M. R. Rudnick and R. M. Cohen, “A Controlled Trial of Recombinant Human Erythropoietin and Nandrolone Decanoate in the Treatment of Anemia in Patients on Hcronic Hemodialysis,” Clinical Nephrology, Vol. 37, No. 5, 1992, pp. 264-267.
W. J. Gaughan, K. A. Liss, S. R. Dunn, et al., “A 6-Month Study of Low-Dose Recombinant Human Erythropoietin Alone and in Combination with Androgens for the Treatment of Anemia in Chronic Hemodialysis Patients,” American Journal of Kidney Diseases, Vol. 30, No. 4, 1997, pp. 495-500. doi:10.1016/S0272-6386(97)90307-3
H. Sheashaa, W. Abdel-Razek, A. El-Husseini, et al., “Use of Nandrolone Decanoate as an Adjuvant for Erythropoietin Dose Reduction in Treating Anemia in Patients On Hemodialysis,” Nephron Clinical Practice, Vol. 99, No. 4, 2005, pp. c102-c106.
A. V. Kshirsagar, C. Poole, A. Mottl, D. Shoham, N. Franceschini, G. Tudor, M. Agrawal, C. Denu-Ciocca, E. Magnus Ohman and W. F. Finn, “N-Acetylcysteine for the Prevention of Radiocontrast Induced Nephropathy: A Meta-Analysis of Prospective Controlled Trials,” Journal of the American Society of Nephrology, Vol. 15, No. 3, 2004, pp. 761-769. doi:10.1097/01.ASN.0000116241.47678.49
M. J. Smilkstein, G. L. Knapp, K. W. Kulig, B. H. Rumack, “Efficacy of Oral N-Acetylcysteine in the Treatment of Acetaminophen Overdose. Analysis of the National Multicenter Study (1976 to 1985),” New England Journal of Medicine, Vol. 319, No. 24, 1988, pp. 1557-1562. doi:10.1056/NEJM198812153192401
ACT Investigators, “Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography: Main Results from the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT),” Circulation, Vol. 124, No. 11, 2011, pp. 1250-1259.
“KDIGO Clinical Practice Guideline for Acute Kidney Injury,” Kidney International Supplements, Vol. 2, No. 1, 2012, pp. 8-12. doi:10.1038/kisup.2012.7
S.-P. Hsu, C.-K. Chiang, S.-Y. Yang and C.-T. Chien, “N-Acetylcysteine for the Management of Anemia and Oxidative Stress in Hemodialysis Patients,” Nephron Clinical Practice, Vol. 116, No. 3, 2010, pp. c207-c216.
G. Swarnalatha, R. Ram, P. Neela, M. U. Naidu, K. V. Dakshina Murty, “Oxidative Stress in Hemodialysis Patients Receiving Intravenous Iron Therapy and the Role of N-Acetylcysteine in Preventing Oxidative Stress,” Saudi Journal of Kidney Diseases and Transplantation, 2010, Vol. 21, No. 5, pp. 852-888.
N. A. Finnigan, M. M. Chernick and R. L. Benz, “Nephrology, N-Acetylcysteine (NAC) May Improve Erythropoietin Resistant Anemia (ERA) in Hemodialysis Patients [SA-PO2587] ASN Renal Week 2010 Abstracts.”